Interim analyses and non-comparative efficacy analysis for primary (day 210) and secondary (day 30) end points.
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接:
https://figshare.com/articles/dataset/_Interim_analyses_and_non_comparative_efficacy_analysis_for_primary_day_210_and_secondary_day_30_end_points_/902592
下载链接
链接失效反馈官方服务:
资源简介:
Intention-to-Treat and Per-Protocol complete-case analysis populations were identical at day 30 & day 210.
Exact binomial 95% confidence interval (CI).
One-sided 97.5% confidence interval.
Multiple versus 7.5 mg/kg single dose; p-value = 0.015 (Fisher's exact test): Dose escalation rule met; increase dosage to 10 mg/kg & continue recruitment.
Multiple versus 10 mg/kg single dose; p value = 0.748 from chi-square test of difference between arms: Dose escalation rule not met; continue recruitment (same dosage in single-dose arm).
Includes patients in Interim analysis 2. Multiple versus 10 mg/kg single dose; p-value = 0.196 from chi-square test of difference between arms: Dose escalation rule not met; concerns arose regarding low cure in each arm and recruitment not continued.
8 patients lost to follow-up by day 210 (all from the multiple-dose arm).
创建时间:
2014-01-16



